Mbunya. S. Misiani: From the WFH Congress to Meaningful Change for Patients with Bleeding Disorders Worldwide
Mbunya. S. Misiani, Principal Consultant at Dr Mbunya Health and Leadership Consultancy, shared on LinkedIn:
”A bit of a late post: Honored and privileged to have attended my 3rd Congress of the World Federation of Hemophilia (WFH),an extraordinary global gathering that brought together patients, healthcare professionals, researchers, policymakers, industry partners, and advocates committed to improving the lives of people living with bleeding disorders.
The congress provided a unique platform to engage with the latest advancements in hemophilia care, gene therapies, diagnostics, comprehensive care models, data systems, and patient-centered approaches that are transforming outcomes across the world.
It was also a valuable opportunity to contribute to scientific discourse through abstract presentations and knowledge exchange with colleagues from different regions.
One of the most impactful experiences was walking alongside patients, families, and advocates from around the globe.
These moments served as a powerful reminder that behind every scientific breakthrough and policy discussion are individuals and families whose lives are directly affected by bleeding disorders.
Their stories of resilience, courage, and hope continue to inspire our collective efforts.
As an African healthcare professional and advocate, I left the congress with a strong conviction that Africa must be an active participant and beneficiary of the remarkable progress being made globally.
While significant advances have been achieved in diagnosis, treatment, and comprehensive care, many individuals across Africa still face challenges related to delayed diagnosis, limited access to treatment, inadequate laboratory services, and shortages of specialized healthcare personnel.
The future of bleeding disorder care must include equitable access to innovations, strengthened healthcare systems, investment in local capacity building, improved laboratory infrastructure, expanded screening programs, robust patient registries, and sustainable partnerships that address the unique needs of African communities.
We must work collectively to ensure that no patient is left behind simply because of where they were born.
The knowledge, partnerships, and experiences gained from this congress will undoubtedly contribute to ongoing efforts to improve patient care, strengthen advocacy initiatives, support research, and expand educational opportunities across Africa.
By working together, we can build a future where every person living with a bleeding disorder has access to timely diagnosis, quality care, and the opportunity to live a full and productive life.
My sincere gratitude to the World Federation of Hemophilia, fellow delegates, patients, colleagues, and partners who continue to champion this important mission.
The conversations did not end with the congress—they must translate into action, collaboration, and measurable impact for patients worldwide, especially in underserved regions.”
Stay updated with Hemostasis Today.
-
Jun 11, 2026, 07:59Uday Sankar Akash Vankayala: Key Findings on IBD-Associated VTE Phenotypes and Inpatient Burden
-
Jun 11, 2026, 07:41Zia Ullah: Hidden Cerebral Venous Sinus Thrombosis After Dengue Recovery
-
Jun 11, 2026, 07:24Aaron Rodriguez Calienes: RESISTANT Registry Provides Reassuring Safety Data for Acute Intracranial Stenting
-
Jun 11, 2026, 07:06Bernard Slater Jr.: Hemophilia B Reminds You that No Matter How Strong You Are, You Are Still Human
-
Jun 11, 2026, 05:11Daniel I McIsaac: Less Blood Loss and No Excess VTE with Tranexamic Acid in High-Risk Surgery
-
Jun 11, 2026, 05:03Aymeric Couturier: Lessons from the TRACK Trial on Anticoagulation in Advanced CKD
-
Jun 11, 2026, 04:53Umut Kocabas: Current Practice and Guideline Adherence on Cancer-Associated Thrombosis in Turkey
-
Jun 11, 2026, 04:40Fernanda Orsi: Which Obstetric APS Patients Are More Likely to Develop Thromboses?
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See